Literature DB >> 3117825

Automated analysis of mitomycin C in body fluids by high-performance liquid chromatography with on-line sample pre-treatment.

U R Tjaden1, E A de Bruijn, R A van der Hoeven, C Jol, J van der Greef, H Lingeman.   

Abstract

A fully automated liquid chromatographic system for the bioanalysis of mitomycin C has been described. The isolation of the analyte from the biological matrix (plasma, ascites and urine) is performed using a continuous-flow system equipped with a dialysis membrane in order to remove proteins. The samples are concentrated on a reversed-phase pre-column and subsequently introduced on to a reversed-phase analytical column by applying column-switching techniques. The drug is detected by absorbance measurements at 360 nm. Using the described system up to 100 samples a day can be analysed with determination limits of the order of 1 ng/ml, with a linear dynamic range of at least three decades for plasma and urine samples. The procedure was applied to pharmacokinetic studies of ovarian cancer patients treated intraperitoneally with mitomycin C.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117825     DOI: 10.1016/0378-4347(87)80154-8

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  High mitomycin C concentration in tumour tissue can be achieved by isolated liver perfusion in rats.

Authors:  A Marinelli; D H Pons; J A Vreeken; S K Nagesser; P J Kuppen; U R Tjaden; C J van de Velde
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats.

Authors:  A Marinelli; C J van de Velde; P J Kuppen; H C Franken; J H Souverijn; A M Eggermont
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

3.  Methods for direct determination of mitomycin C in aqueous solutions and in urine.

Authors:  Dolores Marín; Pedro Pérez; Carmen Teijeiro; Emil Palecek
Journal:  Biol Proced Online       Date:  1998-09-17       Impact factor: 3.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.